CRIS Current Research Information System

PELLEGRINI, CINZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.128
NA - Nord America 5.459
AS - Asia 5.342
Continente sconosciuto - Info sul continente non disponibili 277
AF - Africa 264
SA - Sud America 252
OC - Oceania 10
Totale 17.732
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.350
NL - Olanda 2.120
VN - Vietnam 1.563
SG - Singapore 1.432
CN - Cina 1.193
IT - Italia 1.041
DE - Germania 809
GB - Regno Unito 611
SE - Svezia 589
HK - Hong Kong 395
FR - Francia 214
IN - India 211
RU - Federazione Russa 197
BR - Brasile 184
IE - Irlanda 112
KR - Corea 106
UA - Ucraina 100
BD - Bangladesh 98
JP - Giappone 96
FI - Finlandia 89
ZA - Sudafrica 71
CA - Canada 59
TG - Togo 59
CI - Costa d'Avorio 52
EE - Estonia 45
PL - Polonia 41
PH - Filippine 35
TH - Thailandia 32
AT - Austria 31
NG - Nigeria 30
AR - Argentina 29
JO - Giordania 29
SC - Seychelles 28
ID - Indonesia 26
BE - Belgio 24
MX - Messico 22
IQ - Iraq 20
TR - Turchia 19
ES - Italia 18
LT - Lituania 14
TW - Taiwan 13
SA - Arabia Saudita 12
CH - Svizzera 11
BG - Bulgaria 10
IR - Iran 10
AU - Australia 9
MY - Malesia 9
PE - Perù 9
EC - Ecuador 8
PK - Pakistan 8
HR - Croazia 7
JM - Giamaica 7
KE - Kenya 7
LB - Libano 7
RS - Serbia 7
UZ - Uzbekistan 7
CL - Cile 6
GR - Grecia 6
PT - Portogallo 6
PY - Paraguay 6
RO - Romania 6
VE - Venezuela 6
EG - Egitto 5
TN - Tunisia 5
DO - Repubblica Dominicana 4
BY - Bielorussia 3
CR - Costa Rica 3
HN - Honduras 3
HU - Ungheria 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DZ - Algeria 2
GE - Georgia 2
GH - Ghana 2
GT - Guatemala 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
LC - Santa Lucia 2
MD - Moldavia 2
MN - Mongolia 2
NI - Nicaragua 2
OM - Oman 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BM - Bermuda 1
BN - Brunei Darussalam 1
CO - Colombia 1
CU - Cuba 1
ET - Etiopia 1
GY - Guiana 1
IS - Islanda 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 17.447
Salva come PNG Salva come JPEG
Città #
Eygelshoven 1.286
Singapore 1.016
Kerkrade 666
Ashburn 579
Southend 504
Fairfield 471
Frankfurt am Main 380
Hong Kong 365
Chandler 350
Ho Chi Minh City 348
Santa Clara 316
Hanoi 272
Houston 264
San Jose 257
Woodbridge 228
Seattle 226
Hefei 224
Wilmington 191
Bologna 188
Beijing 170
Cambridge 158
Dong Ket 152
Ann Arbor 151
Princeton 145
Boardman 123
Council Bluffs 121
Dublin 112
Milan 104
Seoul 98
Los Angeles 91
New York 86
Lauterbourg 77
Tokyo 77
Helsinki 67
Berlin 66
Lomé 59
Rome 58
Nanjing 57
Westminster 54
Abidjan 52
Padova 49
Da Nang 45
Bremen 43
Haiphong 43
São Paulo 42
Jinan 40
Buffalo 39
Kyiv 36
Dallas 34
San Diego 33
The Dalles 33
Falkenstein 32
Redondo Beach 31
Amman 29
Shenyang 29
Florence 28
Warsaw 28
Chicago 27
Munich 26
Toronto 26
Abeokuta 25
Guangzhou 25
Jacksonville 25
Turin 25
Bengaluru 23
Changsha 23
Hebei 23
London 23
Brooklyn 22
Tianjin 22
Brussels 21
Phoenix 21
Saint Petersburg 21
Dearborn 20
Shanghai 20
Hyderabad 19
Bến Tre 18
Jiaxing 18
Verona 18
Lappeenranta 17
Redmond 17
Amsterdam 16
Biên Hòa 16
Düsseldorf 16
Secaucus 16
Taizhou 16
Catania 15
Nanchang 15
Zhengzhou 15
Des Moines 14
Nuremberg 14
Vienna 14
Bangkok 13
Can Tho 13
Jakarta 13
Orem 13
Rimini 13
Atlanta 12
Johannesburg 12
Modena 12
Totale 11.616
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.875
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 471
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 342
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 258
Metabolic profile evolution in relapsed/refractory B-cell non-Hodgkin lymphoma patients treated with CD19 chimeric antigen receptor T-cell therapy and implications in clinical outcome 258
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 254
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 249
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 245
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 244
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 233
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials. 231
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 228
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 226
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 224
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 218
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 217
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 217
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 216
Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. 212
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 208
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 208
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 206
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 203
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 201
Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study 195
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 195
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 185
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 184
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 182
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 181
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 180
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 177
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 176
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 176
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 176
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 175
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 174
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 169
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase 2 study of FIL ONLUS 169
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 168
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 167
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 165
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 162
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 162
Efficacy of idelalisib as bridge to allogeneic stem cell transplant in relapsed follicular lymphoma: a case report 160
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 160
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 159
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 157
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 157
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 157
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 155
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 152
Brentuximab vedotin in relapsed primary mediastinal large B-cell lymphoma: results from a phase 2 clinical trial 151
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 151
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 149
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 146
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 146
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 145
Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program 145
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 144
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 144
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 142
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 141
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 139
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 138
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. 130
Erythroderma and non-Hodgkin T-cell lymphoma: what else, apart from Mycosis Fungoides and Sézary syndrome? 128
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 127
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 126
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 125
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 123
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 123
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 120
Role of autologous stem cell transplantation in T-cell lymphoma patients: a single institution retrospective analysis 119
Mycosis fungoides: disease evolution of the "lion queen" revisited. 117
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 115
Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience 110
Finalization of autologous stem cell transplant in complex and multirelapsed follicular lymphoma 108
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 88
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 87
TALOs, Fill the Gap: Tafasitamab and Lenalidomide in Diffuse Large B‐Cell Lymphoma in the Real‐Life Patient Journey 83
Brentuximab vedotin in the treatment of relapsed/refractory CD30+ peripheral T-cell lymphoma: A FIL phase 2 study 83
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 82
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report 75
Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report 73
null 69
Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report 68
Pirtobrutinib in relapsed or refractory mantle cell lymphoma: outcomes from the compassionate use program in Italy 64
A Real‐Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B‐Cell Lymphoma. 55
MACOP-B in Adult Langerhans Cell Histiocytosis Confirms Durable Organ Responses at an Updated Long‐Term Follow‐Up 51
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma. 46
Risk factors for persisting SARS-CoV-2 infection in patients with B-cell malignancies in the Omicron era: A multicenter cohort study 45
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients 34
Gemcitabine 32
Immune‐related adverse events in the treatment of Hodgkin lymphoma with immune checkpoint inhibitors 26
Totale 17.732
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.337
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.337
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.263 0 63 93 156 110 67 29 92 52 88 284 229
2022/20231.587 161 240 117 220 122 123 35 119 231 45 97 77
2023/2024510 39 83 32 48 39 59 39 32 19 54 25 41
2024/20252.736 106 300 211 183 402 145 238 117 79 253 149 553
2025/20267.714 412 453 419 336 532 1.591 1.714 184 1.144 463 221 245
2026/2027459 255 204 0 0 0 0 0 0 0 0 0 0
Totale 17.732